Share on

Asia Pacific Next Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2023 to 2028

Published: March, 2023
ID: 5231
Pages: 145
Formats: report pdf report excel report power bi report ppt

The Asia Pacific Next-Generation Antibody Therapeutics Market Size (2023 to 2028):

According to the report, the size of the Asia Pacific Next-Generation Antibody Therapeutics Market is estimated to grow USD 2.02 billion by 2028 from USD 1.01 billion in 2023, growing at a CAGR of 14.9% between 2023 to 2028. It captures 20% of the global market.

Biotechnology and pharmaceutical companies are clinically developing the next-generation antibody therapies for different disease indications accredited to the rise in market growth. Increasing demand for biologics drugs used for treating patients with chronic disorders is leveraging market growth. Rising census count and economies, particularly in developed countries, are projected to lead the market growth. Escalating government support for research and development activities and growing demand for superior healthcare facilities are surging the market demand. A growing number of cancer cases, as the next generation antibody therapy works as an effective therapy accredited to the market growth. Factors like rising government initiatives for supporting research and development activities and developing healthcare infrastructure are fueling the market. New product launches with regular government approvals are incrementing the next-generation antibody therapeutics market demand.

However, the huge capital required for research and development activities in developing antibody therapies negatively affects market growth. The governments of different nations have imposed strict rules and guidelines regarding the usage of antibodies. This factor is curbing the increase in the market. Time taking procedural approvals and limited FDA approvals for drugs and other products restrict the growth in the market.

This research report on the Asia Pacific Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories:

By Therapeutics: 

  • Oncology
  • Autoimmune/Inflammatory Diseases

By Technology: 

  • Antibody-Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments and Antibody-like Proteins
  • Biosimilar Antibody Products

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Based on the region, the Asia Pacific is likely to be the fastest-growing market with the highest CAGR in the forecast period. The economic boom in the emerging economies of India and China are the reasons for this.

The Asia-pacific market is accredited due to factors like increasing antibody-drug conjugate usage and rapid growth in biosimilar antibodies and engineered antibodies creating new opportunities for the market demand. Increasing research and development activities united with crucial players to manufacture adequate and enhanced drugs escalates the market demand. China is leading the market with the largest share. The market in China is driven by the government, spending considerable investments in improving healthcare during the COVID-19 pandemic. The escalating number of cost-efficient research services is majorly contributing to the market growth. Japan and China are next to China in leading the next-generation antibody therapeutics market. Rising advancements among the monoclonal antibody technology are likely to foster market growth. A growing number of government initiatives regarding the research and development of drug development and increasing disposable income positively influence the market demand. The rest of APAC is expected to have noticeable growth in the market.

Some of the notable companies dominating the Asia Pacific Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample